Francia, S. http://orcid.org/0000-0001-8091-1266
Shmal, D. http://orcid.org/0000-0001-6770-6364
Di Marco, S. http://orcid.org/0000-0003-4847-6270
Chiaravalli, G.
Maya-Vetencourt, J. F. http://orcid.org/0000-0003-3808-8944
Mantero, G. http://orcid.org/0000-0003-3381-1400
Michetti, C. http://orcid.org/0000-0003-4402-6985
Cupini, S. http://orcid.org/0000-0003-4090-5739
Manfredi, G.
DiFrancesco, M. L. http://orcid.org/0000-0002-7511-4438
Rocchi, A. http://orcid.org/0000-0002-1334-9063
Perotto, S. http://orcid.org/0000-0002-9678-7455
Attanasio, M.
Sacco, R.
Bisti, S.
Mete, M.
Pertile, G. http://orcid.org/0000-0003-4951-0549
Lanzani, G. http://orcid.org/0000-0002-2442-4495
Colombo, E. http://orcid.org/0000-0002-7998-9397
Benfenati, F. http://orcid.org/0000-0002-0653-8368
Article History
Received: 14 October 2021
Accepted: 14 June 2022
First Online: 27 June 2022
Competing interests
: The P3HT-NP technology is the subject of the US patent application US 16/005,248 “<i>Eye-injectable polymeric nanoparticles and method of use therefor</i>” by Istituto Italiano di Tecnologia and Ospedale Sacro Cuore Don Calabria that was submitted June 11, 2018, and is currently licensed to Novavido s.r.l.—a company that develops organic retinal prostheses. The Authors declare the following competing interests: F.B., G.L. and G.P. are inventors in the patent application and cofounders of Novavido s.r.l.; F.B. and G.L. are scientific consultants of Novavido s.r.l. The other authors declare no competing interests.